dc.contributor.author |
Repsold, Lisa
|
|
dc.contributor.author |
Pretorius, Etheresia
|
|
dc.contributor.author |
Joubert, Annie M.
|
|
dc.date.accessioned |
2014-09-02T06:30:37Z |
|
dc.date.available |
2014-09-02T06:30:37Z |
|
dc.date.issued |
2014-06-07 |
|
dc.description.abstract |
BACKGROUND: 2-Methoxyestradiol is known to have antitumour and antiproliferative action in vitro and in vivo.
However, when 2-methoxyestradiol is orally administered, it is rapidly oxidized by the enzyme 17β-hydroxysteriod
dehydrogenase in the gastrointestinal tract. Therefore, 2-methoxyestradiol never reaches high enough concentrations
in the tissue to be able to exert these antitumour properties. This resulted in the in silico-design of 2-methoxyestradiol
analogues in collaboration with the Bioinformatics and Computational Biology Unit (UP) and subsequent synthesis by
iThemba Pharmaceuticals (Pty) Ltd (Modderfontein, Midrand, South Africa). One such a novelty-designed analogue is
2-ethyl-3-O-sulphamoyl-estra-1, 3, 5(10)16-tetraene (ESE-16).
METHODS: This pilot study aimed to determine the morphological effect and possible generation of reactive
oxygen species by ESE-16 on erythrocytes and platelet samples (with and without added thrombin) by means
of scanning electron microscopy, transmission electron microscopy and flow cytometry.
RESULTS: Erythrocytes and platelets were exposed to ESE-16 at a concentration of 180nM for 24 hours. Scanning- and
transmission electron microscopy indicated that ESE-16 did not cause changes to erythrocytes, platelets or fibrin networks.
Flow cytometry measurements of hydrogen peroxide and superoxide indicated that ESE-16 does not cause an increase in
the generation of reactive oxygen species in these blood samples.
CONCLUSION: Further in vivo research is warranted to determine whether this novel in silico-designed analogue may impact
on development of future chemotherapeutic agents and whether it could be considered as an antitumour agent. |
en_US |
dc.description.librarian |
am2014 |
en_US |
dc.description.uri |
http://www.cancerci.com/content/14/1/48 |
en_US |
dc.identifier.citation |
Repsold, L, Pretorius, E & Joubert, AM 2014, 'An estrogen analogue and promising anticancer agent refrains from inducing morphological damage and reactive oxygen species generation in erythrocytes, fibrin and platelets : a pilot study', Cancer Cell International, vol. 14, art. 48, pp. 1-8. |
en_US |
dc.identifier.issn |
1475-2867 (print) |
|
dc.identifier.issn |
1475-2867 (online) |
|
dc.identifier.other |
10.1186/1475-2867-14-48 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/41882 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
BioMed Central |
en_US |
dc.rights |
© 2014 Repsold et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License. |
en_US |
dc.subject |
2-Methoxyestradiol analogues |
en_US |
dc.subject |
Reactive oxygen species |
en_US |
dc.subject |
Cancer |
en_US |
dc.subject |
2-ethyl-3-O-sulphamoyl-estra-1, 3, 5(10)16-tetraene (ESE-16) |
en_US |
dc.title |
An estrogen analogue and promising anticancer agent refrains from inducing morphological damage and reactive oxygen species generation in erythrocytes, fibrin and platelets : a pilot study |
en_US |
dc.type |
Article |
en_US |